TOKYO/MUMBAI — The global pharmaceutical industry is bracing for major supply chain disruptions as the Trump administration explores new tariffs on the sector, with producers of generic treatments in India and elsewhere seen suffering a particularly heavy blow.
The U.S. imported $246.8 billion of medicinal, dental and pharmaceutical products in 2024, according to data from the Commerce Department. Outpacing imports of passenger cars, this amounted to 7.6% of all U.S. goods imports for the year.
